Midatech Announces the Opening of cGMP Standard Facility
News May 07, 2007
Midatech Group Ltd has announced the opening of its specialist design and manufacturing facility for cGMP grade nanoparticles in Bilbao, Spain.
Midatech Biogune S.L. is said to be the world’s first cGMP grade manufacturing plant for the production of nanoparticles at a scale commensurate with pharmaceutical applications.
Staffed by an experienced, multi-disciplined team, the plant will initially focus on the design and manufacture of nanoparticles to supply Midatech Group’s series of projects applying nanotechnology for therapeutic purposes.
These include using nanoparticles as scaffolds for synthetic vaccines and antibiotics, as drug delivery vehicles for RNAi drugs and drugs able to cross the blood brain barrier, as well as targeted cancer treatments and imaging agents.
Midatech’s nanoparticles will allow drug companies to deliver new and existing medicines at lower doses and with greater specificity, thereby reducing toxicity.
Speaking on the opening, Managing Director of Biogune Justin Barry stated “We are delighted to launch the new facility in the dynamic environment of the Zamudio Science Park. We are very proud of the capabilities and future potential of the site which represent a real step forward in realising the potential of nanoparticles for medical advancement. We would like to thank both the Basque regional government and the Zamudio Science Park whose support and dedication has been invaluable in helping us to realise our objective.”
Midatech Biogune will be exhibiting at the upcoming BIO Boston conference, May 6-9 in Boston, USA at booth number 1087 in the Spain pavilion.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.